Welcome to our dedicated page for Ocular Therapeut news (Ticker: OCUL), a resource for investors and traders seeking the latest updates and insights on Ocular Therapeut stock.
Ocular Therapeutix, Inc. reports news around ophthalmic drug development, commercial product activity and corporate governance for a Nasdaq-listed biopharmaceutical company using ELUTYX proprietary bioresorbable hydrogel formulation technology. Recurring updates focus on AXPAXLI, also known as OTX-TKI, an axitinib intravitreal hydrogel candidate for retinal disease, including wet age-related macular degeneration and diabetic retinal disease such as non-proliferative diabetic retinopathy.
Company announcements also cover DEXTENZA, an FDA-approved corticosteroid for ocular inflammation and pain following ophthalmic surgery and ocular itching associated with allergic conjunctivitis, as well as OTX-TIC, a travoprost intracameral hydrogel program for open-angle glaucoma or ocular hypertension. Other recurring items include financial results, scientific and investor conference participation, clinical-study presentations and inducement equity grants under Nasdaq Listing Rule 5635(c)(4).
Ocular Therapeutix (NASDAQ: OCUL) reported second quarter 2026 results and detailed progress on its AXPAXLI (OTX-TKI) retina franchise. According to Ocular Therapeutix, an NDA for AXPAXLI in wet AMD is planned for Q4 2026 under the Section 505(b)(2) pathway, following a positive FDA Type C meeting and a pre-NDA meeting scheduled for Q3 2026. The filing will rely on SOL-1 Week 52 efficacy and safety data plus interim SOL-R safety data, targeting an aggregate safety set of over 300 patients with at least one year of exposure.
A post-hoc SOL-1 analysis suggested up to an estimated 72% reduction in treatment burden versus projected on-label aflibercept (2 mg) over 60 weeks. Cash and equivalents were $598.6 million at June 30, 2026, with projected runway into 2028. Q2 2026 net revenue was $13.5 million, flat year over year, and net loss was $(78.8) million, or $(0.35) per share, as R&D, selling and marketing, and G&A expenses all increased to support Phase 3 trials and commercial readiness for a potential 2027 launch, if approved.
Ocular Therapeutix (NASDAQ: OCUL) granted inducement equity awards to eleven newly hired non-executive employees under its 2019 Inducement Stock Incentive Plan, consistent with Nasdaq Listing Rule 5635(c)(4).
Awards, effective July 6, 2026, include options for 34,700 shares at $9.66 and 11,375 RSUs with multi‑year vesting schedules.
Ocular Therapeutix (NASDAQ: OCUL) plans several July 2026 scientific and investor appearances. The company will present at the OIS Retina Innovation Summit on July 14 in Montréal and at the ASRS 44th Annual Meeting July 15–18, highlighting OTX-TKI Phase 3 SOL-1 results and nAMD data.
Ocular will also join the HC Wainwright 6th Annual Ophthalmology Virtual Conference on July 22 with a webcast fireside chat for investors.
Ocular Therapeutix (NASDAQ: OCUL) granted inducement equity awards to new SVP, Market Access and Health Policy, Kelley Allison, under its 2019 Inducement Stock Incentive Plan in line with Nasdaq Rule 5635(c)(4).
Awards include options for 85,000 shares at $8.99 and 28,000 RSUs with multi‑year vesting.
Ocular Therapeutix (NASDAQ: OCUL) plans to submit a U.S. FDA‑aligned NDA for AXPAXLI™ in wet AMD in 4Q 2026. The filing will rely on SOL‑1 Week 52 efficacy and safety plus interim SOL‑R safety to exceed 300 treated patients, using the 505(b)(2) pathway.
SOL‑R efficacy data will not be in the NDA; the trial will remain masked to Week 96 to assess new secondary endpoints versus aflibercept, with topline results expected in 1Q 2028. The company will also prioritize a single global Phase 3 DR trial, HELIOS‑3, evaluating once‑yearly AXPAXLI.
Ocular Therapeutix (NASDAQ: OCUL) granted Nasdaq Rule 5635(c)(4) inducement equity awards to seven new non-executive employees under its 2019 Inducement Stock Incentive Plan.
The June 1, 2026 grants include options for 51,775 shares at $8.93 and 16,950 RSUs with multi‑year vesting.
Ocular Therapeutix (NASDAQ:OCUL) will participate in Clinical Trials at the Summit 2026 in Las Vegas on June 12-13, 2026. Company leaders and external experts will join fireside chats and panels focused on OTX-TKI and retinal diseases.
Multiple sessions will cover efficacy, safety, and program updates.
Ocular Therapeutix (NASDAQ:OCUL) will host an Investor Day in New York City on June 17, 2026, starting at 2:00 PM ET, with in-person and virtual access.
The event will feature updates on AXPAXLI wet AMD NDA plans, SOL-R and SOL-X trials, and a registrational diabetic retinopathy program.
Ocular Therapeutix (NASDAQ: OCUL) granted inducement equity awards to new SVP, Head of HR, Amy Ricca, under its 2019 Inducement Stock Incentive Plan and Nasdaq Rule 5635(c)(4).
The grants include options for 75,000 shares at $9.28 and 25,000 restricted stock units with multi-year vesting schedules.
Ocular Therapeutix (NASDAQ: OCUL) granted inducement equity awards to twelve newly hired non-executive employees effective May 4, 2026 under its 2019 Inducement Stock Incentive Plan pursuant to Nasdaq Rule 5635(c)(4).
The awards include non-statutory stock options to purchase an aggregate of 127,650 shares and restricted stock units totaling 41,550 shares; option exercise price is $9.71 per share, equal to the closing market price on the grant date. Options have a ten-year term and vest over four years; RSUs vest in three equal annual installments.